Abstract
Background The impact of RWE publication on use of approved therapies—including the existence of an effect and timing of impact—is unknown.
Methods We assessed the relationship between the cadence of RWE publications and sales of sacubitril/valsartan (Entresto®) following launch. Publication data were derived from a PubMed search over 7/01/2015–12/31/2023 for English-language, human subjects’ studies with the drug name (Entresto® or sacubitril) and indication (heart failure) in the title or abstract. Quarterly RWE publication data were combined with quarterly information on sacubitril/valsartan sales over the 34-quarter period spanning Q3 2015 through Q4 2023. Quarter-to-quarter change in total sales was modeled with linear regression as a function of counts of previously published RWE-related studies, adjusting for a linear time trend to control for any underlying trends in sales growth; change in total sales from the quarter prior to publication to the quarter of publication to control for recent sales changes; and the cumulative count of RWE publications from Q3 2015 through the previous quarter to control for the contribution of previous RWE publications to future sales.
Results The PubMed search identified 888 studies; of these, 333 (37.5%) were classified as RWE-related. An additional RWE-related publication (in quarter q) was associated with an estimated mean increase in quarterly sales of $1.8M (from quarter q to q+1 following publication), $3.5M (from q+1 to q+2), and $2.7M (from q+2 to q+3). In adjusted models, an additional RWE publication was associated with a mean gain in sales from quarter q+1 to q+2 of $2.6M (95% CI −$0.2M to $5.4M). RWE publications were not associated with an increase in sales in the quarter following publication, and the association was attenuated by third quarter following publication.
Conclusion RWE studies were associated with increased use of sacubitril/valsaratan, providing preliminary evidence of RWE’s ability to support therapy adoption.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The authors have no financial conflicts of interest related to this work to disclose.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
